14 results on '"Van der Merwe S"'
Search Results
2. SARS-CoV-2 anti-spike IgG antibodies are present in all liver transplant recipients after fifth vaccine dose.
- Author
-
Smeets JJH, van Malenstein H, van der Merwe S, Nevens F, and Verbeek J
- Subjects
- Humans, Male, Middle Aged, Female, Transplant Recipients, Aged, Liver Transplantation, Immunoglobulin G blood, Immunoglobulin G immunology, SARS-CoV-2 immunology, Antibodies, Viral blood, Antibodies, Viral immunology, COVID-19 prevention & control, COVID-19 immunology, Spike Glycoprotein, Coronavirus immunology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage
- Published
- 2024
- Full Text
- View/download PDF
3. Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH.
- Author
-
Boesch M, Lindhorst A, Feio-Azevedo R, Brescia P, Silvestri A, Lannoo M, Deleus E, Jaekers J, Topal H, Topal B, Ostyn T, Wallays M, Smets L, Van Melkebeke L, Härtlova A, Roskams T, Bedossa P, Verbeek J, Govaere O, Francque S, Sifrim A, Voet T, Rescigno M, Gericke M, Korf H, and van der Merwe S
- Subjects
- Humans, Endothelial Cells metabolism, Liver metabolism, Macrophages metabolism, Adipose Tissue metabolism, Inflammation metabolism, Non-alcoholic Fatty Liver Disease complications
- Abstract
Background & Aims: In non-alcoholic fatty liver disease (NAFLD), monocytes infiltrate visceral adipose tissue promoting local and hepatic inflammation. However, it remains unclear what drives inflammation and how the immune landscape in adipose tissue differs across the NAFLD severity spectrum. We aimed to assess adipose tissue macrophage (ATM) heterogeneity in a NAFLD cohort., Methods: Visceral adipose tissue macrophages from lean and obese patients, stratified by NAFLD phenotypes, underwent single-cell RNA sequencing. Adipose tissue vascular integrity and breaching was assessed on a protein level via immunohistochemistry and immunofluorescence to determine targets of interest., Results: We discovered multiple ATM populations, including resident vasculature-associated macrophages (ResVAMs) and distinct metabolically active macrophages (MMacs). Using trajectory analysis, we show that ResVAMs and MMacs are replenished by a common transitional macrophage (TransMac) subtype and that, during NASH, MMacs are not effectively replenished by TransMac precursors. We postulate an accessory role for MMacs and ResVAMs in protecting the adipose tissue vascular barrier, since they both interact with endothelial cells and localize around the vasculature. However, across the NAFLD severity spectrum, alterations occur in these subsets that parallel an adipose tissue vasculature breach characterized by albumin extravasation into the perivascular tissue., Conclusions: NAFLD-related macrophage dysfunction coincides with a loss of adipose tissue vascular integrity, providing a plausible mechanism by which tissue inflammation is perpetuated in adipose tissue and downstream in the liver., Impact and Implications: Our study describes for the first time the myeloid cell landscape in human visceral adipose tissue at single-cell level within a cohort of well-characterized patients with non-alcoholic fatty liver disease. We report unique non-alcoholic steatohepatitis-specific transcriptional changes within metabolically active macrophages (MMacs) and resident vasculature-associated macrophages (ResVAMs) and we demonstrate their spatial location surrounding the vasculature. These dysfunctional transcriptional macrophage states coincided with the loss of adipose tissue vascular integrity, providing a plausible mechanism by which tissue inflammation is perpetuated in adipose tissue and downstream in the liver. Our study provides a theoretical basis for new therapeutic strategies to be directed towards reinstating the endogenous metabolic, homeostatic and cytoprotective functions of ResVAMs and MMacs, including their role in protecting vascular integrity., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Outcomes of minor versus major papilla rendez-vous for EUS-guided pancreatic duct drainage.
- Author
-
Bronswijk M, Persyn D, van Malenstein H, Laleman W, and van der Merwe S
- Subjects
- Female, Humans, Male, Middle Aged, Cholangiopancreatography, Endoscopic Retrograde, Drainage methods, Endosonography methods, Pancreatic Ducts diagnostic imaging, Pancreatic Ducts surgery, Retrospective Studies, Treatment Outcome, Aged, Ampulla of Vater, Pancreatitis, Chronic
- Abstract
Objectives: EUS-guided pancreatic duct drainage (EUS-PD) using rendez-vous has been suggested as a safer alternative to pancreatogastrostomy. Fibrostenotic disease in the pancreatic head may however preclude major papilla rendez-vous, leading to preferential guidewire advancement through the minor papilla. Our aim was to compare the outcomes of minor and major papilla rendez-vous., Methods: This is a tertiary single-center retrospective analysis of all consecutive EUS-PD procedures performed from 2015 to April 2022. EUS-PD was only performed following failed retrograde attempts. Successful EUS-PD rendez-vous cases were included and minor and major papilla procedures were compared., Results: Thirty-three patients were included in the final analysis (66.6% male, mean age 56.1 [SD±14.8] years, 54.6% active smokers). In 21 patients (63.6%), minor papilla rendez-vous was attained. Clinical success was achieved in 81.0% vs. 58.3% in the major papilla group (p = 0.230). The overall incidence of AE was similar in both groups (9 [42.9%] vs. 4 [33.3%] events, p = 0.719), with a comparable distribution in severe, moderate and mild AE. Incidence of recurrent pancreatitis was almost identical (28.6% vs. 25.0%, p = 1.000)., Conclusions: For patients with symptomatic chronic pancreatitis, EUS-PD using minor or major papilla rendez-vous attained similar results, suggesting that pancreatic duct drainage through the minor papilla can be considered as equally effective., Competing Interests: Conflict of interest Michiel Bronswijk and Diederik Persyn declare no competing interests. Schalk van der Merwe holds the Cook chair in Interventional endoscopy and holds consultancy agreements with Cook, Pentax and Olympus. Wim Laleman co-chairs the Boston-Scientific Chair in Therapeutic Biliopancreatic Endoscopy with Schalk Van der Merwe and has consultancy agreements with Boston Scientific and Cook. Hannah van Malenstein holds a consultancy agreement with Boston-Scientific., (Copyright © 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. The use of endoscopic ultrasound in the diagnosis and management of portal hypertension.
- Author
-
Laleman W, Vanderschueren E, Van der Merwe S, and Chang KJ
- Subjects
- Humans, Endosonography adverse effects, Gastrointestinal Hemorrhage diagnostic imaging, Gastrointestinal Hemorrhage etiology, Gastrointestinal Hemorrhage therapy, Hypertension, Portal diagnostic imaging, Hypertension, Portal therapy, Hypertension, Portal complications, Esophageal and Gastric Varices diagnostic imaging, Esophageal and Gastric Varices etiology, Esophageal and Gastric Varices therapy
- Abstract
The role of endoscopic ultrasound in the diagnosis and management of chronic liver disease is rapidly increasing. It forms one of the major backbones of endo-hepatology and brings us a step closer to personalized medicine. This review will focus on the particular use of EUS in the diagnosis and management of cirrhotic portal hypertension and potential complications hereof, such as ascites and gastrooesophageal varices. More specifically, EUS-guided Porto-systemic Pressure Gradient (EUS-PPG) measurement, EUS-guided coil and glue embolization of gastric varices, EUS-guided paracentesis and EUS-guided intrahepatic portosystemic shunt creation (IPSS) will be discussed in-depth with regard to clinical status, available data and technical considerations., (Copyright © 2022. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
6. The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
- Author
-
Van der Merwe S, Chokshi S, Bernsmeier C, and Albillos A
- Subjects
- Causality, Humans, Preventive Medicine methods, Preventive Medicine trends, Acute-On-Chronic Liver Failure etiology, Acute-On-Chronic Liver Failure prevention & control, Bacterial Infections immunology, Bacterial Infections therapy, Liver Cirrhosis complications, Liver Cirrhosis immunology, Liver Cirrhosis microbiology, Liver Cirrhosis physiopathology
- Abstract
Infections, due to a dysfunctional immune response, pose a great risk to patients with decompensated cirrhosis and herald the beginning of the terminal phase of this disease. Infections typically result from breaches in innate immune barriers and inadequate clearance by immune cells. This leads to bacterial and bacterial product translocation to the systemic circulation, which is already primed by ongoing hepatic inflammation in patients with cirrhosis, who are particularly prone to developing organ failure in the presence of an infection. Early identification of bacterial infection, along with the prompt use of appropriate antibiotics, have reduced the mortality associated with certain infections in patients with decompensated cirrhosis. Judicious use of antibiotic therapy remains imperative given the emergence of multidrug-resistant infections in the cirrhotic population. Important research over the last few years has identified molecular targets on immune cells that may enhance their function, and theoretically prevent infections. Clinical trials are ongoing to delineate the beneficial effects of targeted molecules from their off-target effects. Herein, we review the mechanisms that predispose patients with cirrhosis to bacterial infections, the clinical implications of infections and potential targets for the prevention or treatment of infections in this vulnerable population., Competing Interests: Conflict of interest The authors do not report any conflict of interest in relation to the content of this article. Please refer to the accompanying ICMJE disclosure forms for further details., (Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
7. Use of hyperglycemic clamp to assess pancreatectomy and islet cell autotransplant in patient with heterotaxy syndrome and dorsal pancreas agenesis leading to chronic pancreatitis.
- Author
-
De Paep DL, Gillard P, Ling Z, Verbeke H, Maleux G, Vandecaveye V, Debaveye Y, Keymeulen B, van der Merwe S, Pipeleers D, Pirenne J, van Malenstein H, and Jacobs-Tulleneers-Thevissen D
- Subjects
- Autografts, Female, Humans, Pancreas diagnostic imaging, Pancreas surgery, Pancreatectomy, Transplantation, Autologous, Treatment Outcome, Heterotaxy Syndrome, Insulin-Secreting Cells, Islets of Langerhans Transplantation, Pancreatitis, Chronic surgery
- Abstract
Patients with heterotaxy syndrome (HS) can present with an associated complete dorsal pancreas agenesis (DPA). They are considered to be at increased risk for developing diabetes due to a reduced functional beta cell mass (FBM) as well as for chronic pancreatitis leading to unmanageable pain. We report the case of a young woman with chronic pancreatitis due to HS and associated DPA. She presented with a severe persisting upper abdominal pain refractory to nonsurgical treatment. Unlike in previously reported cases, she had a high FBM (ie, 150% of normoglycemic controls) as determined by hyperglycemic clamp. She underwent a total pancreatectomy followed within 24 hours by an intraportal autologous islet cell transplant containing 4 × 10
6 beta cells (4700 islet equivalent)/kg body weight. After surgery, the pain resolved, eliminating the need for analgesics. The intraportal implant established an adequate FBM (72% of controls at posttransplant month 2), achieving glycemic control without need for insulin administration. A hyperglycemic clamp can assess the utility and efficacy of an intraportal islet cell autotransplant following total pancreatectomy in patients with HS and complete DPA., (© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.)- Published
- 2020
- Full Text
- View/download PDF
8. Innate immune cells in cirrhosis.
- Author
-
Bernsmeier C, van der Merwe S, and Périanin A
- Subjects
- Acute-On-Chronic Liver Failure etiology, Disease Progression, Humans, Immunotherapy methods, Acute-On-Chronic Liver Failure immunology, Immunity, Innate physiology, Liver Cirrhosis complications, Liver Cirrhosis immunology, Liver Cirrhosis therapy
- Abstract
Cirrhosis is a multisystemic disease wherein inflammatory responses originating from advanced liver disease and its sequelae affect distant compartments. Patients with cirrhosis are susceptible to bacterial infections, which may precipitate acute decompensation and acute-on-chronic liver failure, both of which are associated with high short-term mortality. Innate immune cells are an essential first line of defence against pathogens. Activation of liver macrophages (Kupffer cells) and resident mastocytes generate proinflammatory and vaso-permeating mediators that induce accumulation of neutrophils, lymphocytes, eosinophils and monocytes in the liver, and promote tissue damage. During cirrhosis progression, damage- and pathogen-associated molecular patterns activate immune cells and promote development of systemic inflammatory responses which may involve different tissues and compartments. The antibacterial function of circulating neutrophils and monocytes is gradually and severely impaired as cirrhosis worsens, contributing to disease progression. The mechanisms underlying impaired antimicrobial responses are complex and incompletely understood. This review focuses on the continuous and distinct perturbations arising in innate immune cells during cirrhosis, including their impact on disease progression, as well as reviewing potential therapeutic targets., Competing Interests: Conflict of interest The authors do not report any conflict of interest in relation to the content of this article. Please refer to the accompanying ICMJE disclosure forms for further details., (Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
9. Reversal of protein-losing enteropathy following surgical revision of a jejunal Roux-en-Y loop after liver transplantation: Look for lymphangiectasia!
- Author
-
Bronswijk M, Harlet R, Monbaliu D, Van der Merwe S, Pirenne J, and Vanuytsel T
- Subjects
- Anastomosis, Roux-en-Y, Humans, Jejunum, Reoperation, Liver Transplantation, Protein-Losing Enteropathies
- Published
- 2019
- Full Text
- View/download PDF
10. Reply to: "Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF".
- Author
-
van der Merwe S, Laleman W, Langouche L, and Meersseman P
- Subjects
- Critical Illness, Hospitalization, Humans, Intensive Care Units, Liver Cirrhosis, Acute-On-Chronic Liver Failure
- Published
- 2019
- Full Text
- View/download PDF
11. Improved survival after LTx-associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single-center experience and systematic review.
- Author
-
Minnee RC, Fieuws S, Jochmans I, Aerts R, Sainz Barriga M, Debaveye Y, Maertens J, Vandenberghe P, Laleman W, van der Merwe S, Verslype C, Cassiman D, Ferdinande P, Nevens F, Pirenne J, and Monbaliu D
- Subjects
- Adult, Aged, Female, Follow-Up Studies, Graft Rejection drug therapy, Graft Rejection etiology, Graft Survival, Graft vs Host Disease drug therapy, Graft vs Host Disease etiology, Humans, Liver Transplantation adverse effects, Male, Middle Aged, Postoperative Complications, Prognosis, Retrospective Studies, Risk Factors, Survival Rate, Antibodies, Monoclonal therapeutic use, Graft Rejection mortality, Graft vs Host Disease mortality, Interleukin-2 Receptor alpha Subunit antagonists & inhibitors, Liver Transplantation mortality, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Acute graft-versus-host disease (GVHD) after liver transplant (LTx) is a rare complication with a high mortality rate. Recently, monoclonal antibody (mAb) treatment, specifically with anti-interleukin 2 receptor antibodies (IL2RAb) and anti-tumor necrosis factor-α antibodies (TNFAb), has gained increasing interest. However, evidence is mostly limited to case reports and the efficacy remains unclear. Here, we describe 5 patients with LTx-associated GVHD from our center and provide the results of our systematic literature review to evaluate the potential therapeutic benefit of IL2RAb/TNFAb treatment. Of the combined population of 155 patients (5 in our center and 150 through systematic search), 24 were given mAb (15.5%)-4 with TNFAb (2.6%) and 17 with IL2RAb (11%) ("mAb group")-and compared with patients who received other treatments (referred to as "no-mAb group"). Two-sided Fisher exact tests revealed a better survival when comparing treatment with mAb versus no-mAb (11/24 vs 27/131; P = .018), TNFAb versus no-mAb (3/4 vs 27/131; P = .034), and IL2RAb versus no-mAb (8/17 vs 27/131; P = .029). This systematic review suggests a beneficial effect of mAb treatment and a promising role for TNFAb and IL2RAb as a first-line strategy to treat LTx-associated acute GVHD., (© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2018
- Full Text
- View/download PDF
12. Combined liver and lung transplantation with extended normothermic lung preservation in a patient with end-stage emphysema complicated by drug-induced acute liver failure.
- Author
-
Ceulemans LJ, Monbaliu D, Verslype C, van der Merwe S, Laleman W, Vos R, Neyrinck A, Van Veer H, De Leyn P, Nevens F, Pirenne J, Verleden G, and Van Raemdonck D
- Subjects
- Emphysema complications, Female, Humans, Liver Failure complications, Middle Aged, Emphysema surgery, Liver Failure surgery, Liver Transplantation, Lung Transplantation
- Abstract
Isolated lung transplantation (LuTx) and liver transplantation are established treatments for irreversible lung and liver failure. Combined liver and lung transplantation (cLiLuTx) is a less common, but approved therapy of combined organ failure, mostly applied in patients suffering from progressive cystic fibrosis and advanced liver disease. We report a patient who was listed for LuTx due to end-stage chronic obstructive pulmonary disease and who developed drug-induced acute hepatic failure. The only therapeutic option was hyper-urgent cLiLuTx. To correct the poor coagulation in order to reduce the per-operative risk of bleeding, the liver was transplanted first. In anticipation of the longer lung preservation time, cold flushed lungs were preserved on a portable lung perfusion device for ex vivo normothermic perfusion for 11 h 15 min, transplanted sequentially off-pump, and reperfused after a total ex vivo time of 13 h 32 min and 16 h for the first and second lung, respectively. Ten months later, the patient is doing well and no rejection occurred. Normothermic ex vivo lung perfusion may help to prolong preservation time, facilitating long-distance transport and combined organ transplantation., (© Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2014
- Full Text
- View/download PDF
13. Quantitation of hydroxyproline in bone by gas chromatography-mass spectrometry.
- Author
-
Delport M, Maas S, van der Merwe SW, and Laurens JB
- Subjects
- Animals, Calibration, Rats, Sensitivity and Specificity, Bone and Bones chemistry, Gas Chromatography-Mass Spectrometry methods, Hydroxyproline analysis
- Abstract
A validated gas chromatography (GC)-mass spectrometric (MS) method for the analysis of hydroxyproline in rat femur is reported. Hydroxyproline in bone hydrolysates was extracted with an anion exchange resin and the N(O)-tert-butyldimethylsilyl derivatives analyzed by GC-MS. The hydroxyproline concentration was estimated relative to pipecolic acid, 3,4-dehydroproline and n-tetracosane as internal standards. The mass-to-charge ratios (m/z) for the ions used for quantitation by single ion monitoring were 314 m/z for hydroxyproline, 198 m/z for pipecolic acid, 256 m/z for dehydroproline and 57 m/z for n-tetracosane. A coefficient of variation of 5.8% was achieved and the limit of detection was calculated to be 0.233 micromol/l bone hydrolysate.
- Published
- 2004
- Full Text
- View/download PDF
14. Pericardial disease is often not recognised as a cause of chronic severe ascites.
- Author
-
Van der Merwe S, Dens J, Daenen W, Desmet V, and Fevery J
- Subjects
- Adolescent, Ascites etiology, Cardiac Catheterization, Chronic Disease, Diagnosis, Differential, Echocardiography, Doppler, Female, Humans, Magnetic Resonance Imaging, Male, Pericarditis, Constrictive complications, Tomography, X-Ray Computed, Ascites diagnosis, Pericarditis, Constrictive diagnosis
- Abstract
Background/aims: Severe chronic ascites remains a difficult diagnostic and therapeutic problem. Even in the current era, constrictive pericarditis is an underestimated and sometimes unrecognised cause. Moreover, missing the diagnosis deprives patients of remedial therapy., Methods: Two cases of calcified constrictive pericarditis, complicated with cirrhosis and diagnosed in a late stage, are described. Due to insufficient clinical appreciation and lack of trust in echocardiography results, performed by cardiologists who were insufficiently familiar with the echocardiographic features of constrictive pericarditis, diagnosis was delayed in the two patients, Results: The diagnosis of constrictive pericarditis as a cause of ascites is based upon the clinical signs of right heart failure in a patient with normal systolic left and right ventricular function and a high, serumascitic albumin-content difference. Complementary workup with complete Doppler echocardiography study, right and left heart catheterisation and MRI or cine CT of the heart is necessary to confirm the diagnosis., Conclusion: Careful history taking and clinical examination remain the cornerstone of any diagnostic work-up, even in this era of technological refinement.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.